Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: accolade.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $13.00 → $8.00 | Buy | Needham |
| 2/26/2024 | $16.00 | Outperform | Leerink Partners |
| 1/17/2024 | $16.00 → $14.00 | Neutral | DA Davidson |
| 1/3/2024 | $13.00 | Equal Weight | Barclays |
| 5/24/2023 | $16.50 | Neutral → Buy | BofA Securities |
| 4/12/2023 | $18.00 | Overweight | Stephens |
| 3/23/2023 | $16.00 | Neutral → Buy | Guggenheim |
| 2/9/2023 | $14.00 | Buy → Hold | Jefferies |
| 2/2/2023 | $15.00 | Outperform | Raymond James |
| 9/8/2022 | $12.00 | Overweight | Piper Sandler |
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. Stephens Annual Investment Conference | NASH2024 in Nashville on Wednesday, November 20 at 9:00 am CTCG MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21. (1x1 meetings, no webcast)Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5 at 10:00 am ET. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and the
Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). SEATTLE, Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions. Employers' health costs are expected
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0b6b999c6e7b47fdb26d7e8a774df09f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a live a
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigati
LITTLE ROCK, Ark., Aug. 22, 2024 /PRNewswire/ -- Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers. According to Bryan Dorathy, Celeste's Vice President of Innovation, Celeste will appeal to employers who want to see their employees' health improve while also helping them better navigate the healthcare system. Often, employers offer a variety of health solut
SEATTLE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston on Wednesday, August 14 at 12:00 pm ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-cl
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad6356ede4b179553cca22ec02b2f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4 at 2:00 pm CT. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are bu
The partnership combines Noom's best-in-class content and coaching with Accolade's advanced primary care physicians SEATTLE, May 21, 2024 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) announced today that Noom has joined Accolade's Trusted Partner Ecosystem to provide customers with a comprehensive solution for weight loss and metabolic health, including support for GLP-1s and other anti-obesity medications. In addition to the standard integrated features that drive appropriate Trusted Partner utilization, Noom's clinical obesity management solution, Noom Med, will be powered by Accolade physicians extensively trained in weight loss protocols and advanced primary care. The addition of Noom to
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo
With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en
Accolade welcomes executive vice president and chief human resources officer Jennifer Hanson to create an amazing employee experience for the company that partners with human resource leaders to deliver Personalized Healthcare SEATTLE, May 2, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the appointment of Jennifer Hanson as chief human resources officer, executive vice president of people and culture, reporting to Accolade CEO, Rajeev Singh. Hanson will oversee
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously
Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00
DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously
Barclays initiated coverage of Accolade with a rating of Equal Weight and set a new price target of $13.00
BofA Securities upgraded Accolade from Neutral to Buy and set a new price target of $16.50
Stephens initiated coverage of Accolade with a rating of Overweight and set a new price target of $18.00
Guggenheim upgraded Accolade from Neutral to Buy and set a new price target of $16.00
Jefferies downgraded Accolade from Buy to Hold and set a new price target of $14.00
Raymond James initiated coverage of Accolade with a rating of Outperform and set a new price target of $15.00
Piper Sandler resumed coverage of Accolade with a rating of Overweight and set a new price target of $12.00
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $6.
Stifel analyst David Grossman maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $8.
Truist Securities analyst Jailendra Singh maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $14 to $9.
Morgan Stanley analyst Ricky Goldwasser maintains Accolade (NASDAQ:ACCD) with a Equal-Weight and lowers the price target from $12 to $6.
Barclays analyst Stephanie Davis maintains Accolade (NASDAQ:ACCD) with a Equal-Weight and lowers the price target from $11 to $5.5.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Aflac Incorporated (NYSE:AFL) from $95 to $100. Piper Sandler analyst John Barnidge maintained an Overweight rating. Aflac shares fell 0.1% to close at $89.16 on Thursday. See how other analysts view this stock. Truist Securities slashed the price target for NIKE, Inc. (NYSE:NKE) from $99 to $81. Truist Securities analyst Joseph Civello maintained a Hold rating. NIKE shares gained 0.1% to close at $94.19 on Thursday. See how other analysts view this stock.
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.2% on Friday. Shares of NIKE, Inc. (NYSE:NKE) fell sharply in today's pre-market trading following fourth-quarter earnings and soft FY25 guidance. Analysts at Stifel and Morgan Stanley downgraded the stock following the report. NIKE shares dipped 15.6% to $79.42 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Accolade, Inc. (NASDAQ:ACCD) shares tumbled 32.1% to $4.34 in pre-market trading after the company reported first-quarter financial results and issued worse-than-expected FY25 revenue guidance. Also, Needham maintained a Buy rating
Canaccord Genuity analyst Richard Close maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $16 to $13.
Needham analyst Ryan MacDonald maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $8.
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0b6b999c6e7b47fdb26d7e8a774df09f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a live a
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad6356ede4b179553cca22ec02b2f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024. "Accolade has built a rare healthcare services business at scale with consistently strong growth rates. Whether serving consumers, employers, health plans, or government entities, the core of our value proposition is making healthcare easier to access, navigate, and consume for our members. We provide a unique blend of healthcare services and next generation technology that will further differentiate us in FY 2025 as we approach $500 million in revenues and forecast full year positive Adjusted EBITDA," said Rajeev S
SEATTLE, April 03, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal fourth quarter 2024 financial results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI5dc020b8e7534a2ab2036759667cf1a2) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be acc
SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal third quarter ended November 30, 2023. "As we head into the new year, Accolade continues to define the future of how healthcare should be experienced in this country. Our unique combination of people and technology is creating a new model for improving health outcomes and helping our more than 10 million members live healthier lives. We are closing the physician gap, improving access to care, and leveraging AI and other innovations to make the system work better for our employer customers, their employees and their families. The results can be seen in our growing custom
SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2024 financial results on Monday, January 8, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0aea659c422c4c259198c9c7e6313d1b). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2023. "We are halfway through the 2024 fiscal year and the demand environment for our solutions remains strong. Accolade continues to lay the foundation to build a lasting, scalable business that will improve people's lives and fundamentally change the way healthcare is experienced in this country. Accolade's unique combination of advocacy and care solutions is changing the way employers deliver healthcare to their employees and their families, and the success of this strategy is evident in our growing customer base which now totals more
SEATTLE, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 financial results on Wednesday, October 4, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI8e60ea64fd184d8d8660a125ccc80055). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Liste
Accolade exceeds guidance for fiscal first quarter and raises guidance for fiscal year 2024 SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal first quarter ended May 31, 2023. "Our consistently strong financial results reinforce our belief that an advocacy-led care delivery strategy is the key to transforming the U.S. healthcare system. We are seeing the proof points in our growing customer base and sales momentum, and also through our customers' outcomes, engagement and measurable ROI. We are especially excited by the growth we are witnessing in virtual primary care, which is the key to people living their healthiest